Development of an automated method for the determination of human paraoxonase1 activity

1. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmaco. 2005; 69:541-50.10.1016/j.bcp.2004.08.027Search in Google Scholar

2. Akgür SA, Oztürk P, Solak I, Moral AR, Ege B. Human serum paraoxonase (PON1) activity in acute organophosphorus insecticide poisoning. Forensic Sci Int. 2003; 133:136-40.10.1016/S0379-0738(03)00060-4Search in Google Scholar

3. Rochu D, Chabriere E, Masson P. Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology. 2007; 233:47-59.10.1016/j.tox.2006.08.037Search in Google Scholar

4. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 2000; 101:252-7.10.1161/01.CIR.101.19.2252Search in Google Scholar

5. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca, S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer. 2007; 7:48-56.10.1186/1471-2407-7-48Open DOISearch in Google Scholar

6. Mackness MI. Why plasma should not be used to study paraoxonase. Atherosclerosis. 1998; 136:195-6.10.1016/S0021-9150(97)00197-4Search in Google Scholar

7. Draganov DI, Teiber JF, Audrey S, Yoichi O, Roger S, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005; 46:1239-47.10.1194/jlr.M400511-JLR200Open DOISearch in Google Scholar

8. Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton AP. Paraoxonase 1 gene polymorphisms and Parkinson’s disease in a Finnish population. Neurosci Lett. 2004; 367:168-70.10.1016/j.neulet.2004.05.108Search in Google Scholar

9. Kondo I, Mitsutoshi Y. Genetic polymorphism of paraoxonase 1 and susceptibility to Parkinson’s disease. Brain Res. 1998; 806:271-3.10.1016/S0006-8993(98)00586-1Search in Google Scholar

10. Cellini E, Tedde A, Bagnoli S, Nacmia B, Piacentini S, Bessi V. Association analysis of the paraoxonase-1 gene with Alzheimer’s disease. Neurosci Lett. 2006; gene with the risk of developing Alzheimer’s disease. Neurobiol Aging. 2006; 27:1212-5.Search in Google Scholar

11. Chapuis J, Boscher M, Bensemain F, Cottel D, Amouyel P, Lambert JC. Association study of the paraoxonase1Search in Google Scholar

12. Kalmar T, Seres I, Balogh Z, Kaplar G, Paragh G. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab. 2005; 31:574-80.10.1016/S1262-3636(07)70233-1Search in Google Scholar

13. Ikeda Y, Inoue M, Suehiro T, Arii K, Kumon Y, Hashimoto K. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol. 2009; 46:239-42.10.1007/s00592-008-0066-318830558Search in Google Scholar

14. Gugliucci A, Mehlhalf K, Kinugasa E, Ogata H, Schulze K, Kimura S. Paraoxonase1 concentrtions in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adducts clearance. Clin Chim Acta. 2007; 377:213-20.10.1016/j.cca.2006.09.02817118352Search in Google Scholar

15. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998; 9: 2082-8.10.1681/ASN.V91120829808094Search in Google Scholar

16. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics. 2006; 16:183-90.10.1097/01.fpc.0000189796.21770.d316495777Search in Google Scholar

17. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000; 28: 1335-42.Search in Google Scholar

18. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol. 2009; 235:1-9.10.1016/j.taap.2008.11.001304542819071155Open DOISearch in Google Scholar

19. Marsillach J, Ferré N, Vila MC, Lligona A, Mackness B, Mackness M, et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem. 200; 740:645-50.10.1016/j.clinbiochem.2007.01.02017335791Search in Google Scholar

20. Ferre N, Camps J, Marsillach J, Mackness B, Mackness M, Coll B, Tous M, Joven J. Comparison of paraoxonase 1 measurements in serum and in lithium-heparinanticoagulated plasma samples. Clin Chem. 2005; 51: 922-3.10.1373/clinchem.2005.04823115855675Open DOISearch in Google Scholar

21. Huen K, Richter R, Furlong C, Eskenazi B, Holland N. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta. 2009; 402:67-4.10.1016/j.cca.2008.12.019268367319146843Search in Google Scholar

22. Charlton-Menysa V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem. 2006; 52:453-7.10.1373/clinchem.2005.06341216423902Open DOISearch in Google Scholar

23. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat Struct Mol Bio. 2004; 11: 412-9.10.1038/nsmb76715098021Open DOISearch in Google Scholar

24. Rochu D, Renault F, Elias M, CleryBarraud C, Chabriere E, Masson P. Stability of highly purified human paraoxonase: Association with human phosphate binding protein is essential for preserving its active conformation(s). Biochim Biophys Acta. 2007; 1774: 874-83. 408:199-02.10.1016/j.bbapap.2007.05.00117556053Search in Google Scholar